中國宏橋(01378.HK)獲控股股東增持合共687萬股
格隆匯6月14日丨中國宏橋(01378.HK)公吿,公司董事會獲通知,公司控股股東中國宏橋控股有限公司已於2024年6月14日從公開市場以每股平均價約11.87港元購買合共687萬股公司股份,相當於截至本公吿日期公司已發行股份總數約0.073%。
於增持股份後,宏橋控股持有6,083,386,073股股份,相當於公司已發行股份總數約64.20%。根據公司獲授的相關公眾持股量豁免,公司須滿足的公眾持股量為15.04%。根據公司可以得悉的公開資料及就董事所知,公司在增持股份後依然能夠滿足公眾持股量的要求。
增持股份反映了宏橋控股對集團未來前景及長期發展的信心。宏橋控股不排除未來於適時進一步增持公司的股份。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.